{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:54:03Z","timestamp":1772160843057,"version":"3.50.1"},"reference-count":44,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Oral Diseases"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the prevalence of cutaneous and oral immune\u2010related adverse events (irAEs) in cancer patients, risk factors for its development, and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>This retrospective observational study which included 748 medical records of cancer patients who received immune checkpoint inhibitors (ICIs). Demographic and clinicopathological characteristics were collected and analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Most patients were male (59.4%), with stage IV cancer (65%) and received pembrolizumab (46.7%). Four hundred fourteen (55.34%) patients developed cutaneous lesions, 84 (11.2%) developed oral mucosal lesions, and 70 (9.3%) developed xerostomia. The median time for irAEs development was 11\u2009weeks for cutaneous and oral mucosal lesions, and 21.5\u2009weeks for xerostomia. Patients who received PD\u20101\u2009+\u2009CTLA\u20104 had a higher risk for developing cutaneous irAEs (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001), while those who underwent ICI and concurrent chemotherapy had a higher risk (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008) for developing oral mucosal lesions. Patients who presented oral and cutaneous irAEs had better OS than those who did not present (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Cutaneous effects affected more than half of the patients, while oral effects and xerostomia were found in around 11% and 9% of patients, respectively. Concurrent chemotherapy and PD\u20101\u2009+\u2009CTLA\u20104 were more associated with oral and cutaneous irAEs, respectively. Patients who developed such irAEs had better overall survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/odi.15056","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T02:03:52Z","timestamp":1719540232000},"page":"278-285","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Oral and cutaneous immune\u2010related adverse events in cancer patients: Prevalence and overall survival"],"prefix":"10.1111","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9046-3783","authenticated-orcid":false,"given":"Osias Vieira","family":"de Oliveira Filho","sequence":"first","affiliation":[{"name":"Department of Stomatology A.C. Camargo Cancer Center  S\u00e3o Paulo SP Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana Lameiras","family":"Gibbons","sequence":"additional","affiliation":[{"name":"Department of Dermatology A.C. Camargo Cancer Center  S\u00e3o Paulo SP Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri de Lima","family":"Medeiros","sequence":"additional","affiliation":[{"name":"Department of Stomatology A.C. Camargo Cancer Center  S\u00e3o Paulo SP Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thiago Bueno","family":"de Oliveira","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology A.C. Camargo Cancer Center  S\u00e3o Paulo SP Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathaniel Simon","family":"Treister","sequence":"additional","affiliation":[{"name":"Division of Oral Medicine and Dentistry Brigham and Women's Hospital  Boston Massachusetts USA"},{"name":"Department of Oral Medicine, Infection and Immunity Harvard School of Dental Medicine  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3372-1536","authenticated-orcid":false,"given":"Fabio Abreu","family":"Alves","sequence":"additional","affiliation":[{"name":"Department of Stomatology A.C. Camargo Cancer Center  S\u00e3o Paulo SP Brazil"},{"name":"Department of Stomatology S\u00e3o Paulo University  S\u00e3o Paulo SP Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hed.27646"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21388"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oooo.2020.06.014"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2023.106664"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16311"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000239"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219890659"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0805-8"},{"issue":"6","key":"e_1_2_11_12_1","first-page":"318","article-title":"Oral immune\u2010related adverse events caused by immune checkpoint inhibitors: A retrospective study","volume":"71","author":"Di Cosola M.","year":"2022","journal-title":"Minerva Dental and Oral Science"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70122-1"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194781"},{"issue":"8","key":"e_1_2_11_15_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0255716","article-title":"Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta\u2010analysis","volume":"16","author":"Garrett N. F. M. S.","year":"2021","journal-title":"PLoS One"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102134"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000260"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.7697"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/scd.12887"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.7567"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/odi.13964"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/froh.2022.968157"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14043"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000302"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0128"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0131-9"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475420943260"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14205"},{"issue":"3","key":"e_1_2_11_29_1","first-page":"114","article-title":"Sicca\/Sj\u00f6gren's syndrome triggered by PD\u20101\/PD\u2010L1 checkpoint inhibitors. Data from the international ImmunoCancer registry (ICIR)","volume":"37","author":"Ramos\u2010Casals M.","year":"2019","journal-title":"Clinical and Experimental Rheumatology"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/2324709620914796"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.10.014"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.03.026"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/odi.13218"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.2226"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14284"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.08.030"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.07.008"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.36401\/JIPO-23-14"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2020.790"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010-w1"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24098188"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0823"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33436"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04425-z"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12030736"}],"container-title":["Oral Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/odi.15056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T16:02:35Z","timestamp":1739203355000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/odi.15056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1111\/odi.15056"],"URL":"https:\/\/doi.org\/10.1111\/odi.15056","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/ODI.15056\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/ODI.15056\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/ODI.15056\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/ODI.15056\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/ODI.15056\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/ODI.15056\/v3\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/ODI.15056\/v3\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/ODI.15056\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/ODI.15056\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/ODI.15056\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/ODI.15056\/v2\/response1","asserted-by":"object"}]},"ISSN":["1354-523X","1601-0825"],"issn-type":[{"value":"1354-523X","type":"print"},{"value":"1601-0825","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,27]]},"assertion":[{"value":"2024-03-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}